Myelodysplastic Syndromes: all 2,165 studies

Page 5 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.

• Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic SyndromesActive, not recruitingNCT03399773Phase 2Results posted
• DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT03358719Phase 1Results posted
• Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood CancerTerminatedNCT03333486Phase 2Results posted
• Posaconazole Prophylaxis During ATG Treatment for hMDS/AA PatientsCompletedNCT03318159Phase 2Results posted
• Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AMLCompletedNCT03306264Phase 3Results posted
• Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With PembrolizumabTerminatedNCT03286114Phase 1Results posted
• Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic MalignanciesTerminatedNCT03272633Early Phase 1Results posted
• Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)CompletedNCT03268954Phase 3Results posted
• Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion BurdenTerminatedNCT03263091Phase 3Results posted
• Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell TransplantationTerminatedNCT03246906Phase 2Results posted
• Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase InhibitorsCompletedNCT03238248Phase 2Results posted
• GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological MalignanciesTerminatedNCT03214666Phase 1/2Results posted
• Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood DisordersTerminatedNCT03198234Phase 1Results posted
• Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced ThrombocytopeniaTerminatedNCT03195010Phase 2Results posted
• Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantActive, not recruitingNCT03192397Phase 1/2Results posted
• A Study of ONO-7475 in Patients With Acute LeukemiasTerminatedNCT03176277Phase 1/2Results posted
• IGF-MTX Conjugate in the Treatment of Myelodysplastic SyndromeTerminatedNCT03175978Phase 1/2Results posted
• Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With CancerCompletedNCT03154190Not applicableResults posted
• A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic SyndromesTerminatedNCT03151304Phase 2Results posted
• Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)TerminatedNCT03150004Phase 2Results posted
• Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)CompletedNCT03140280Phase 2Results posted
• High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell TransplantCompletedNCT03128359Phase 2Results posted
• Safety and Activity of Digoxin With Decitabine in Adult AML and MDSTerminatedNCT03113071Phase 1/2Results posted
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
• Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic SyndromeStatus unknownNCT03094637Phase 2Results posted
• Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT03092674Phase 2/3Results posted
• Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid NeoplasmsCompletedNCT03072043Phase 1/2Results posted
• Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeTerminatedNCT03067571Phase 2Results posted
• Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic SyndromeCompletedNCT03047993Phase 1/2Results posted
• Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and NeutropeniaCompletedNCT03019939Phase 2Results posted
• Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCTCompletedNCT03018223Phase 1Results posted
• Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) TreatmentCompletedNCT03011034Phase 2Results posted
• Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood CancerTerminatedNCT02999854Phase 3Results posted
• Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme MalignanciesTerminatedNCT02991898Phase 2Results posted
• Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCTCompletedNCT02989844Phase 2Results posted
• Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell TransplantationCompletedNCT02981914Early Phase 1Results posted
• Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT02953561Phase 1/2Results posted
• Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic SyndromeTerminatedNCT02943668Phase 2Results posted
• Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating AgentsCompletedNCT02936752Phase 1Results posted
• Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)TerminatedNCT02929498Phase 1/2Results posted
• Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDSCompletedNCT02921061Phase 1/2Results posted
• Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAsCompletedNCT02907359Phase 3Results posted
• Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid LeukemiaActive, not recruitingNCT02890329Phase 1Results posted
• Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant PatientsTerminatedNCT02877082Phase 2Results posted
• A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic SyndromesTerminatedNCT02848001Phase 1Results posted
• A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)CompletedNCT02842827Phase 1/2Results posted
• A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT02807558Phase 2Results posted
• HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation CyclophosphamideCompletedNCT02793544Phase 2Results posted
• A Study of Pevonedistat in Adult East Asian ParticipantsCompletedNCT02782468Phase 1Results posted
• Tipifarnib in Subjects With Myelodysplastic SyndromesTerminatedNCT02779777Phase 2Results posted
• An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)CompletedNCT02775903Phase 2Results posted
• Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and RecoveryCompletedNCT02767388Results posted
• Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid NeoplasmsCompletedNCT02756572Phase 2Results posted
• Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal MelanomaTerminatedNCT02743611Phase 1/2Results posted
• Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic MalignanciesCompletedNCT02743351Phase 1/2Results posted
• Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDSCompletedNCT02730299Phase 3Results posted
• Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02728050Phase 1/2Results posted
• UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
• Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic SyndromesTerminatedNCT02721875Phase 1Results posted
• Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 MutationCompletedNCT02719574Phase 1/2Results posted
• An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced MalignanciesTerminatedNCT02712905Phase 1/2Results posted
• Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesTerminatedNCT02711137Phase 1/2Results posted
• Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDSTerminatedNCT02706899Phase 1/2Results posted
• Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell TransplantCompletedNCT02684162Phase 2Results posted
• WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT02666950Phase 2Results posted
• A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.TerminatedNCT02663752Phase 2Results posted
• Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid LeukemiaCompletedNCT02658487Phase 2Results posted
• The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS PatientsTerminatedNCT02648932Phase 2Results posted
• Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesCompletedNCT02639559Phase 2Results posted
• A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic SyndromesCompletedNCT02631070Phase 3Results posted
• Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDSCompletedNCT02626715Phase 2Results posted
• An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)CompletedNCT02610777Phase 2Results posted
• Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)TerminatedNCT02599649Phase 2Results posted
• Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Active, not recruitingNCT02598661Phase 2/3Results posted
• Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD ProphylaxisCompletedNCT02593123Phase 2Results posted
• Reduced Intensity Conditioning Transplant Using Haploidentical DonorsCompletedNCT02581007Phase 2Results posted
• Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02566304Phase 2Results posted
• Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft MalignanciesCompletedNCT02556931Phase 2Results posted
• Nivolumab in AML in Remission at High Risk for RelapseCompletedNCT02532231Phase 2Results posted
• Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down SyndromeActive, not recruitingNCT02521493Phase 3Results posted
• A Phase 1 Study of AMG 330 in Subjects With Myeloid MalignanciesTerminatedNCT02520427Phase 1Results posted
• 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02509546Phase 1/2Results posted
• IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk LeukemiaTerminatedNCT02508324Phase 2Results posted
• Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell TransplantActive, not recruitingNCT02506933Phase 2Results posted
• Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical DonorCompletedNCT02500550Phase 2Results posted
• Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CRCompletedNCT02497404Phase 2Results posted
• A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDSCompletedNCT02488408Phase 1/2Results posted
• Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)TerminatedNCT02469415Phase 2Results posted
• Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT02464657Phase 1/2Results posted
• Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell TransplantationCompletedNCT02458235Phase 2Results posted
• Study of Clinical Efficacy and Safety of Tosedostat in MDSCompletedNCT02452346Phase 2Results posted
• Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger PatientsTerminatedNCT02433483Phase 2Results posted
• CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or LymphomaCompletedNCT02424968Phase 2Results posted
• Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT02399917Phase 2Results posted
• Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02397720Phase 2Results posted
• Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT02396134Phase 2Results posted
• The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) StudyCompletedNCT02390414Results posted
• Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual DiseaseTerminatedNCT02370888Phase 1Results posted
• A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML PatientsCompletedNCT02367456Phase 1Results posted
• GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell TransplantTerminatedNCT02360111Not applicableResults posted

← Myelodysplastic Syndromes overview